Benzinga | Jan 7, 2021 07:35AM EST

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021

* Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR)

* Anticipates submitting an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML)

* Expects to submit an IND or IND-equivalent in 2H 2021 for NTLA-2002 for the treatment of hereditary angioedema (HAE)

* Plans to nominate at least one new development candidate in 2021 from broad research efforts and continued platform innovation

* Ended 2020 in strong financial position with $597M in cash